CYCC - Cyclacel Pharmaceuticals Inc Stock Price, Fair Value and News

2.26USD-0.08 (-3.42%)Delayed

Market Summary

USD2.26-0.08

Delayed

-3.42%

CYCC Stock Price

View Fullscreen

CYCC RSI Chart

CYCC Valuation

Market Cap

3.0M

Price/Earnings (Trailing)

-0.15

Price/Sales (Trailing)

6.64

EV/EBITDA

-0.01

Price/Free Cashflow

-0.31

CYCC Price/Sales (Trailing)

CYCC Profitability

EBT Margin

-5061.69%

Return on Equity

892.88%

Return on Assets

-319.5%

Free Cashflow Yield

-326.93%

CYCC Fundamentals

CYCC Revenue

Revenue (TTM)

449.0K

Rev. Growth (Qtr)

93.75%

CYCC Earnings

Earnings (TTM)

-19.7M

Earnings Growth (Yr)

49.24%

Earnings Growth (Qtr)

44.11%

Breaking Down CYCC Revenue

Last 7 days

-0.4%

Last 30 days

15.3%

Last 90 days

-23.9%

Trailing 12 Months

-74.9%

How does CYCC drawdown profile look like?

CYCC Financial Health

Current Ratio

0.58

CYCC Investor Care

Shares Dilution (1Y)

57.70%

Diluted EPS (TTM)

-21.97

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	449.0K	0	0	0
2023	0	0	0	420.0K
2022	0	0	0	0
2021	0	0	0	0
2020	0	0	0	0
2019	0	0	0	0
2018	0	0	0	150.0K
2016	1.6M	1.5M	987.0K	843.0K
2015	1.9M	1.8M	1.8M	1.9M
2014	1.3M	1.4M	1.8M	1.7M
2013	281.0K	519.0K	790.0K	1.1M
2012	668.0K	526.0K	400.0K	230.0K
2011	258.8K	405.5K	552.3K	699.0K
2010	0	0	0	112.0K
2009	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cyclacel Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 29, 2024	schwartz brian	acquired	-	-	12,500	interim chief medical officer
Dec 21, 2023	mcbarron paul	bought	6,252	3.315	1,886	see remarks
Dec 21, 2023	rombotis spiro george	bought	20,122	3.315	6,070	president and ceo
Jun 30, 2023	ferguson kenneth m.	acquired	-	-	21,219	-
Jun 30, 2023	walker karin l	acquired	-	-	21,219	-
Jun 30, 2023	spiegel robert j.	acquired	-	-	21,219	-
Jun 30, 2023	schwartz brian	acquired	-	-	21,219	-
Jun 30, 2023	henney christopher s	acquired	-	-	21,219	-
Jun 30, 2023	barker sam l	acquired	-	-	21,219	-
Jan 31, 2023	kirschbaum mark	acquired	-	-	31,200	chief medical officer

Which funds bought or sold CYCC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	unchanged	-	-45.00	169	-%
May 15, 2024	Altium Capital Management LP	sold off	-100	-101,412	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	418	6,682	8,837	-%
May 15, 2024	Point72 Asset Management, L.P.	unchanged	-	-8,588	32,351	-%
May 14, 2024	Qube Research & Technologies Ltd	unchanged	-	-2.00	6.00	-%
May 13, 2024	UBS Group AG	sold off	-100	-277	-	-%
May 13, 2024	UBS Group AG	new	-	10,202	10,202	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	added	44.33	5,000	44,000	-%
May 10, 2024	OSAIC HOLDINGS, INC.	unchanged	-	-70.00	265	-%
May 10, 2024	ACADIAN ASSET MANAGEMENT LLC	reduced	-41.03	-34,000	29,000	-%

Are Funds Buying or Selling CYCC?

Are funds buying CYCC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CYCC

No. of Funds

Unveiling Cyclacel Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	dellora investments lp	0%	0	SC 13G/A
Feb 14, 2024	schonfeld strategic advisors llc	0.18%	1,900	SC 13G/A
Feb 13, 2024	altium capital management lp	4.99%	37,982	SC 13G/A
Feb 07, 2024	acorn bioventures, l.p.	-	0	SC 13G/A
Jan 10, 2024	altium capital management lp	8.0%	82,032	SC 13G
Jan 04, 2024	lind global fund ii lp	9.9%	102,250	SC 13G
Feb 14, 2023	schonfeld strategic advisors llc	6.14%	770,400	SC 13G
Feb 13, 2023	dellora investments lp	5.2%	648,752	SC 13G/A
Feb 06, 2023	sphera funds management ltd.	1.99%	250,000	SC 13G/A
Jan 26, 2023	acorn bioventures, l.p.	9.99%	2,815,146	SC 13G/A

Recent SEC filings of Cyclacel Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	D	D
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 13, 2024	EFFECT	EFFECT
May 13, 2024	424B3	Prospectus Filed
May 08, 2024	ARS	ARS
May 08, 2024	DEF 14A	DEF 14A
May 08, 2024	DEFA14A	DEFA14A
May 06, 2024	S-1	Initial Public Offering
May 02, 2024	8-K	Current Report

Peers (Alternatives to Cyclacel Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Cyclacel Pharmaceuticals Inc News

Latest updates

Cyclacel Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-6.5%	29,000	31,000	16,000	373,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,168,000	2,572,000	2,472,000	2,424,000	2,793,500	2,348,000	2,337,000	2,204,000
Operating Expenses	-18.7%	4,384,000	5,391,000	6,861,000	6,302,000	7,319,000	8,845,000	-	-	-	-	-	-	-	-	-	-	-	-	-	2,337,000	2,204,000
S&GA Expenses	-15.5%	1,582,000	1,873,000	1,625,000	1,575,000	1,645,000	2,143,000	-	-	-	-	-	-	-	1,753,000	1,497,000	1,309,000	1,318,000	1,363,000	1,285,000	1,184,000	1,192,000
R&D Expenses	-20.4%	2,802,000	3,518,000	5,236,000	4,727,000	5,674,000	6,702,000	-	-	-	-	-	-	-	1,415,000	1,075,000	1,163,000	1,106,000	1,430,500	1,063,000	1,153,000	1,012,000
EBITDA Margin	16.9%	-49.85	-60.02	-190	-186	-182	-170	-152	-149	-152	-145	-125	-104	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	56,000	79,000
Income Taxes	-220.9%	-1,354,000	-422,000	-668,000	-586,000	-1,320,000	-1,581,000	-	-	-	-	-	-	-	-378,500	-281,000	-286,000	-290,000	-448,000	-273,000	-307,000	-268,000
Earnings Before Taxes	24.5%	-4,300,000	-5,693,000	-6,700,000	-6,034,000	-7,124,000	-9,000,000	-	-	-	-	-	-	-	-3,182,000	-2,537,000	-2,452,000	-1,510,000	-2,752,500	-2,174,000	-2,090,000	-2,110,000
EBT Margin	16.8%	-50.62	-60.84	-192	-188	-185	-172	-154	-151	-155	-147	-127	-106	-	-	-	-	-	-	-	-	-
Net Income	44.1%	-2,946,000	-5,271,000	-6,032,000	-5,448,000	-5,804,000	-7,419,000	-	-	-	-	-	-	-	-2,803,500	-2,256,000	-2,166,000	-1,220,000	-2,304,500	-1,901,000	-1,783,000	-1,842,000
Net Income Margin	18.3%	-43.87	-53.70	-164	-158	-152	-141	-125	-123	-127	-123	-107	-91.10	-	-	-	-	-	-	-	-	-
Free Cashflow	87.6%	-483,000	-3,910,000	-4,036,000	-1,305,000	-6,867,000	-5,169,000	-6,968,000	-1,918,000	-6,779,000	-4,551,000	-6,219,000	-4,153,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-30.0%	6.00	9.00	12.00	17.00	23.00	28.00	32.00	36.00	40.00	43.00	45.00	46.00	52.00	37.00	27.00	29.00	13.00	15.00	17.00	19.00	22.00
Current Assets	-35.0%	5.00	7.00	11.00	15.00	19.00	24.00	28.00	32.00	37.00	41.00	43.00	46.00	50.00	35.00	26.00	28.00	12.00	14.00	16.00	18.00	20.00
Cash Equivalents	-17.2%	3.00	3.00	6.00	10.00	11.00	18.00	24.00	29.00	30.00	37.00	40.00	44.00	48.00	33.00	23.00	25.00	9.00	12.00	13.00	15.00	18.00
Net PPE	-22.2%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	2.1%	8.00	8.00	8.00	7.00	8.00	8.00	5.00	5.00	6.00	5.00	4.00	3.00	4.00	4.00	3.00	3.00	3.00	4.00	3.00	4.00	4.00
Current Liabilities	2.3%	8.00	8.00	8.00	7.00	7.00	8.00	4.00	5.00	6.00	5.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	2.00
Shareholder's Equity	-463.4%	-2.21	1.00	4.00	7.00	11.00	16.00	22.00	30.00	34.00	38.00	42.00	43.00	48.00	33.00	24.00	27.00	10.00	12.00	14.00	16.00	18.00
Retained Earnings	-0.7%	-431	-428	-423	-416	-411	-405	-398	-393	-388	-384	-379	-374	-369	-366	-363	-361	-358	-357	-355	-353	-351
Additional Paid-In Capital	0.0%	430	430	428	425	423	423	423	424	423	423	422	419	418	400	389	389	370	370	370	370	370
Shares Outstanding	24.5%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	6.00	-	-	-	11.00	-	-	-	55.00	-	-	-	23.00	-	-	-	9.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	87.6%	-483	-3,910	-4,036	-1,305	-6,861	-5,169	-6,968	-1,915	-6,775	-4,549	-6,210	-4,215	-3,566	-1,152	-2,129	-1,846	-2,807	-1,117	-2,011	-2,635	-3,684
Share Based Compensation	-37.0%	203	322	391	359	401	387	389	350	380	304	320	278	255	141	113	85.00	91.00	105	183	93.00	85.00
Cashflow From Investing	-	-	-	-	-	-6.00	-	-	-3.00	-4.00	-2.00	-9.00	62.00	-78.00	-42.00	-50.00	-	-4.00	6.00	-4.00	-1.00	27.00
Cashflow From Financing	-107.9%	-79.00	999	-50.00	-51.00	-50.00	42.00	1,532	1,474	-50.00	887	2,904	-51.00	17,997	11,348	-50.00	18,256	-50.00	-50.00	-57.00	-101	4,056

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CYCC Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Revenues	$ 29,000	$ 0
Operating expenses:
Research and development	2,802,000	5,674,000
General and administrative	1,582,000	1,645,000
Total operating expenses	4,384,000	7,319,000
Operating loss	(4,355,000)	(7,319,000)
Other income:
Foreign exchange gains (losses)	1,000	(87,000)
Interest income	2,000	116,000
Other income, net	52,000	166,000
Total other income, net	55,000	195,000
Loss before taxes	(4,300,000)	(7,124,000)
Income tax benefit	1,354,000	1,320,000
Net loss	(2,946,000)	(5,804,000)
Dividend on convertible exchangeable preferred shares	0	(50,000)
Net loss applicable to common shareholders	$ (2,946,000)	$ (5,854,000)
Basic and diluted earnings per common share:
Net loss per share - diluted	$ (2.27)	$ (7.00)
Redeemable common shareholders
Basic and diluted earnings per common share:
Net loss per share - diluted	0	(7.00)
Common Stock
Basic and diluted earnings per common share:
Net loss per share - basic	$ (2.27)	$ (7.00)
Clinical trial supply
Revenues:
Revenues	$ 29,000	$ 0

CYCC Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,798	$ 3,378
Prepaid expenses and other current assets	2,037	4,066
Total current assets	4,835	7,444
Property and equipment, net	7	9
Right-of-use lease asset	79	93
Non-current deposits	1,244	1,259
Total assets	6,165	8,805
Current liabilities:
Accounts payable	5,200	3,543
Accrued and other current liabilities	3,150	4,618
Total current liabilities	8,350	8,161
Lease liability	21	37
Total liabilities	8,371	8,198
Stockholders' equity:
Common stock, $0.001 par value; 100,000,000 shares authorized at March 31, 2024 and December 31, 2023; 1,318,259 shares issued and outstanding at March 31, 2024 and 1,058,892 shares issued and outstanding at December 31, 2023	1	1
Additional paid-in capital	429,919	429,796
Accumulated other comprehensive loss	(898)	(908)
Accumulated deficit	(431,228)	(428,282)
Total stockholders' equity	(2,206)	607
Total liabilities and stockholders' equity	6,165	8,805
6% Convertible Exchangeable Preferred Stock
Stockholders' equity:
Preferred stock, value
Series A Convertible Preferred Stock
Stockholders' equity:
Preferred stock, value
Series B Convertible Preferred Stock
Stockholders' equity:
Preferred stock, value

About Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

CEO	Mr. Spiro George Rombotis
WEBSITE	cyclacel.com
INDUSTRY	Biotechnology

Cyclacel Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Cyclacel Pharmaceuticals Inc? What does CYCC stand for in stocks?

CYCC is the stock ticker symbol of Cyclacel Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cyclacel Pharmaceuticals Inc (CYCC)?

As of Fri May 17 2024, market cap of Cyclacel Pharmaceuticals Inc is 2.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CYCC stock?

You can check CYCC's fair value in chart for subscribers.

What is the fair value of CYCC stock?

You can check CYCC's fair value in chart for subscribers. The fair value of Cyclacel Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cyclacel Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CYCC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cyclacel Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CYCC is over valued or under valued. Whether Cyclacel Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Cyclacel Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CYCC.

What is Cyclacel Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CYCC's PE ratio (Price to Earnings) is -0.15 and Price to Sales (PS) ratio is 6.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYCC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cyclacel Pharmaceuticals Inc's stock?

In the past 10 years, Cyclacel Pharmaceuticals Inc has provided -0.572 (multiply by 100 for percentage) rate of return.